


Mesenchymal Stem Cells For

Spinal Cord Injury

Patient Progression Report | January 24, 2022–December 31, 2022


A spinal cord injury (SCI) that damages or severs nerves can cause various levels of paralysis—with loss of strength, sensation, and mobility.

The clinical protocol for SCI patients at BioXcellerator includes four mesenchymal stem cell (MSC) treatments. This report is based on 15 patients treated between January 24 and December 31, 2022. This chart shows the age and gender of patients treated:




Classification of Injury

Spinal cord injuries are classified based on several criteria, including the location of the injury along the spine and the seriousness of impairment. This chart shows patients classified based on the section of the spine—cervical, lumbar, or thoracic—that was injured:



Patients are also classified on seriousness of impairment using the AIS Impairment Scale for Traumatic SCI. This scale evaluates impairment based on four grades. Grades B,C, and D represent incomplete SCI, while Grade A represents complete impairment. The chart below shows the grades of patients treated at BioXcellerator:




Evaluating Treatment Outcomes

Patients were assessed at various intervals based on two evaluation criteria—the Barthel Index for Activities of Daily Living (ADL) and the ASIA (American Spinal Injury Association) scale.

Barthel Index for Activities of Daily Living (ADL)

This questionnaire measures functional independence in terms of personal care and mobility. Of the 10 patients who were evaluated six months after treatment, nine patients assessed their functional independence. A higher number represents more ability to function. This chart shows the score change over the evaluation period.

Figure 4. Level of injury and Barthel scale progression of SCI patients treated with MSCs therapy at BioXcellerator January to June 2022




American Spinal Injury Association (ASIA)

This scale assesses upper and lower extremity impairment with a higher score representing greater recovery. The score ranges from 0 to 100 with a higher score representing the most improvement.

Of the 10 patients who completed the 6-month follow-up, 10 (100%) answered three months after therapy and nine (90%) answered six months after therapy. Our data suggests that more than two treatments are required to demonstrate improvement. This chart shows patient progress based on the ASIA scale:

Figure 5. Level of injury, motor upper and lower extremity total score progression of SCI patients treated with MSCs therapy at BioXcellerator January to June 2022



Note that these patients provided their consent for follow-up using the InCytes web platform and to publish this clinical data. We plan to continue following up with patients and will issue updates when additional data becomes available.

Report By: BioXcellerator Science and Research Team